The primary aim of this study was to document serum levels of IL-18, CXCL9 and IFN-γ in patients with active Still’s–MAS, inactive Still’s–MAS, healthy controls and disease controls (pHLH, or other CTDs without MAS). Here, CXCL9 is linked to macrophage activation syndrome.